Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Metoclopramide is an antiemetic drug which occasionally produced acute dystonic reactions. Although known to interfere with central dopamine mechanisms, it is frequently used in Parkinson's disease to prevent levodopa-induced nausea and vomiting. In this study metoclopramide did not increase Parkinsonism or reduce levodopa-induced involuntary movements in patients with Parkinson's disease. Pimozide, by contrast, increased Parkinsonism and reduced involuntary movements. The capacity of metoclopramide to produce acute dyskinesias while being apparently free of Parkinsonism effects is pharmacologically unique and differentiates this drug from the phenothiazines and butyrophenones.
D000368:Aged; D002230:Carbidopa / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008787:Metoclopramide / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced* / Q000517:prevention & control; D009325:Nausea / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010868:Pimozide / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011398:Promethazine / Q000009:adverse effects / Q000627:therapeutic use
D010919:Placebos; D010868:Pimozide; D007980:Levodopa; D011398:Promethazine; D008787:Metoclopramide; D002230:Carbidopa